Systemic therapeutic options in thymic malignancies: A glimmer of hope

Reviews on Recent Clinical Trials

Volumn 2, Issue 3, 2007, Pages 191-205

  Hammond Thelin, Lisa A ^a   Thomas Jr , Charles R ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Chemotherapy; Targeted therapy; Thymic carcinoma; Thymoma

Indexed keywords

ANGIOPEPTIN; ANTHRACYCLINE; BLEOMYCIN; CARBOPLATIN; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; GEFITINIB; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; INTERLEUKIN 2; IRINOTECAN; MESNA; NAVELBINE; NEDAPLATIN; OCTREOTIDE; PEMETREXED; PLATINUM; PREDNISONE; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

ADJUVANT THERAPY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANAPLASTIC CARCINOMA; ANEMIA; ANGIOGENESIS; ANOREXIA; APOPTOSIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; BILIRUBIN BLOOD LEVEL; BLOOD TOXICITY; CANCER GRADING; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CARCINOID; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DESQUAMATION; DIARRHEA; DISEASE FREE SURVIVAL; DRUG MEGADOSE; DRUG RESPONSE; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; HEART INFARCTION; HUMAN; INFECTION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MESOTHELIOMA; MONOTHERAPY; MUCOSA INFLAMMATION; NAUSEA; NEUROENDOCRINE TUMOR; NEUTROPENIA; OVERALL SURVIVAL; PARESTHESIA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; PROGNOSIS; PURE RED CELL ANEMIA; RECURRENCE RISK; REVIEW; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; SURVIVAL TIME; THORACOTOMY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THYMOMA; THYMUS CANCER;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CISPLATIN; CLINICAL PROTOCOLS; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; CYTOTOXINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; THYMUS NEOPLASMS;

EID: 35048888892     PISSN: 15748871     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488707781662689     Document Type: Review

References (132)

1. Fornasiero A, Daniele O, Ghiotto C, et al. Chemotherapy of invasive thymoma. J Clin Oncol 1990; 8: 1419-23.
2. Rosai J, Sobin LH. Histological typing of tumors of the thymus. In: International Histological Classification of Tumors. (2nd Edition) World Health Organization, Springer Co., New York, NY, USA: 9, 1999.
3. Ohchi T, Tanaka H, Shibuya Y, et al. Thymic carcinoid with mucinous stroma: a case report. Respir Med 1998; 92: 880-2.
4. Zhenqiang G, Kahn L, Bhuiya T. Thymic carcinoid with mucinous stroma. Am Diag Pathol 2006; 10: 114-6.
5. Suster S, Moran CA. Thymic carcinoid with prominent mucinous stroma. Report of a distinctive morphologic variant of thymic neuroendocrine neoplasm. Am J Surg Pathol 1995; 9: 1277-85.
6. Lam WW, Chan FL, Lau YL, Chau MT, Mok CK. Pediatric thymoma: unusual occurrence in two siblings. Pediatr Radiol 1993; 23: 124-6.
7. Marano A, Dritsas C. Familial occurrence of thymoma. Arch Pathol 1973; 95: 90-1.
8. Jensen MO, Antonenko D. Thyroid and thymic malignancy following childhood irradiation. J Surg Oncol 1992; 50: 206-8.
9. Teoh R, McGuire L, Wong K, Chin D. Increased incidence of thymoma in Chinese myasthenia gravis: possible relationship with Epstein-Barr virus. Acta Neurol Scan 1989; 80: 221-5.
10. Dimery IW, Lee JS, Blick M, Pearson G, Spritzer G, Hong WK. Association of Epstein-Barr virus with lymphoepithelioma of the thymus. Cancer 1988; 61: 2475-80.
11. McGuire LJ, Huang DP, Tech R, Arnold M, Wong K, Lee JC. Epstein-Barr virus genome in thymoma and thymic lymphoid hyperplasia. Am J Pathol. 1988; 131: 385-90.
12. Chen PC, Pan CC, Yang AH, Wang LS, Chiang H. Detection of Epstein-Barr virus genome within thymic epithelial tumours in Taiwanese patients by nested PCR, PCR in situ hybridization, and RNA in situ hybridization. J Pathol 2002; 197: 694-8.
13. Herens C, Radermecker M, Servais A, et al. Deletion (6)(p22p25) is a recurrent anomaly of thymoma: report of a second case and review of the literature. Cancer Genet Cytogenet 2003; 146: 66-9.
14. Inoue M, Starostik P, Zettl A, et al. Correlating genetic aberrations with World Health Organization-defined histology and stage across the spectrum of thymomas. Cancer Res 2003; 63: 3708-15.
15. Kubonishi I, Takehara N, Iwata J, et al. Novel t(15:19)(q15;p13) chromosome abnormality in a thymic carcinoma. Cancer Res 1991; 51: 3327-8.
16. Lee ACW, Kwong YL, Fu KH, Chan GCF, Ma L, Lau YL. Disseminated mediastinal carcinoma with chromosomal translocation (15:19). Cancer 1993; 72: 2273-6.
17. Rosai J, Higa E, Davie J. Mediastinal endocrine neoplasm in patients with multiple endocrine adenomatosis: A previously unrecognized association. Cancer 1972; 29: 1075-93.
18. Teh BT, Zedenius J, Kytola S, et al. Thymic carcinoids in multiple endocrine neoplasia type I. Ann Surg 1998; 228: 99-105.
19. Chahinian AP. Thymoma and thymic tumors. In: Kufe DW, Pollock RE, Weishselbaum RR, et al., Eds. Cancer Medicine, Sixth Edition Hamilton, Canada: BC Decker, 2003: 1467-74.
20. Pan CC, Chen PC, Wang LS, Chi KS, Chiang H. Thymoma is associated with an increased risk of second malignancy. Cancer 2001; 92: 2406-11.
21. Engels EA, Pfeiffer RM. Malignant thymoma in the United States: demographic patterns in incidence and associations with subsequent malignancies. Int J Cancer 2003; 105: 546-51.
22. Wang DY, Chang DB, Kuo SH, et al. Carcinoid tumours of the thymus. Thorax. 1994; 49: 357-60.
23. Regnard JF, Magdeleinat P, Dromer C, et al. Prognostic factors and long-term results after thymoma resection: a series of 307 patients. J Thorac Cardiovasc Surg 1996; 112: 376-84.
24. Giaccone G. Treatment of malignant thymoma. Curr Op Oncol 2005; 17: 140-6.
25. Chaer R, Massad MG, Evans A, Snow NJ, Geha AS. Primary neuroendocrine tumors of the thymus. Ann Thorac Surg 2002; 74: 1733-40.
26. Strobel P, Marx A, Zettl A, Muller-Hermelink HK. Thymoma and thymic carcinoma: an update of the WHO classification 2004. Surg Today 2005; 35: 805-11.
27. Ogawa K, Toita T, Uno T, et al. Treatment and prognosis of thymic carcinoma: a retrospective analysis of 40 cases. Cancer 2002; 94: 3115-9.
28. Kondo K, Monden Y. Therapy for thymic epithelial tumors: a clinical study of 1320 patients from Japan. Ann Thorac Surg 2003; 76: 878-84.
29. Klemm KM, Moran CA, Suster S. Pigmented thymic carcinoids: a clinicopathological and immunohistological study of two cases. Mod Pathol 1999; 12: 946-8.
30. Wick MR. Neuroendocrine neoplasia: current concepts. Am J Clin Pathol 2000; 113: 331-5.
31. Detterbeck FC, Parsons AM. Thymic tumors. Ann Thorac Surg 2004; 77: 1860-9.
32. Gal AA, Kornstein MJ, Cohen C, Duarte IG, Miller JI, Mansour KA. Neuroendocrine tumors of the thymus: a clinicopathological and prognostic study. Ann Thorac Surg 2001; 72: 1179-82.
33. Masaoka A, Monden Y, Nakahara Kevin, Tanioka T. Follow-up study of thymomas with special reference to their clinical stages. Cancer 1981; 48: 2485-92.
34. Verley JM, Hollmann KH. Thymoma. A comparative study of clinical stages, histologic features, and survival in 200 cases. Cancer 1985; 55: 1074-86.
35. Maggi G, Casadio C, Cavallo A, Cianci R, Molinatti M, Ruffini E. Thymomas: results of 241 operated cases. Ann Thorac Surg 1991; 51: 152-6.
36. Lewis JE, Wick MR, Scheithauer BW, Bernatz PE, Taylor WF. Thymoma. A clinicopathologic review. Cancer 1987; 60: 2727-43.
37. Cohen DJ, Ronnigen LD, Graeber GM, et al. Management of patients with malignant thymoma. J Thorac Cardiovasc Surg 1984; 87: 301-7.
38. Masaoka A, Yamakawa Y, Niwa H, et al. Thymectomy and malignancy. Eur J Cardiothorac Surg 1994; 8: 251-3.
39. Quintanilla-Martinez L, Wilkens EW, Choi N, Efird J, Hug E, Harris NL. Thymoma. Histologic subclassification is an independent prognostic factor. Cancer 1994; 74: 606-17.
40. Strobel P, Bauer A, Puppe B, et al. Tumor recurrence and survival in patients treated for thymomas and thymic squamous cell carcinoma: a retrospective analysis. J Clin Oncol 2004; 22: 1501-9.
41. Fukai I, Masaoka A, Fujii Y, et al. Thymic neuroendocrine tumor (thymic carcinoid): a clinicopathologic study in 15 patients. Ann Thorac Surg 1999; 67: 208-11.
42. Sperling B, Marschall J, Kennedy R, Pahwa P, Chibbar R. Thymoma: a review of the clinical and pathological findings in 65 cases. Can J Surg 2003; 46; 37-42.
43. Wilkins EJ, Edmunds LH, Castleman B. Cases of thymoma at the Massachusetts General Hospital. J Thorac Cardiovasc Surg 1966; 52: 322-30.
44. Okumura M, Miyoshi S, Takeuchi Y, et al. Results of surgical treatment of thymomas with special reference to the involved organs. J Thorac Cardiovasc Surg 1999; 117: 605-11.
45. Moore KH, McKenzie PR, Kennedy CW, McCaughan BC. Thymoma: trends over time. Ann Thorac Surg 2001; 72: 203-7.
46. Wilkins KB, Sheikh E, Green R, et al. Clinical and pathologic predictors of survival in patients with thymoma. Ann Surg 1999; 230: 562-74.
47. Wang LS, Huang MH, Lin TS, Huang BS, Chien KY. Malignant thymoma. Cancer 1992; 70: 443-50.
48. Penzel R, Hoegel J, Schmitz W, et al. Clusters of chromosomal imbalances in thymic epithelial tumours are associated with the WHO classification and the staging system according to Masaoka. Int J Cancer 2003; 105: 494-8.
49. Boston B. Chemotherapy of invasive thymoma. Cancer 1976; 38: 49-52.
50. Chahinian AP, Holland JF, Bharadwaj S. Chemotherapy for malignant thymoma. Ann Intern Med 1983; 99: 736.
51. Fornasiero A, Daniele O, Ghiotto C, et al. Chemotherapy for invasive thymoma: a 13-year experience. Cancer 1991; 68: 30-3.
52. Loehrer PJ Sr, Kim K, Aisner S, et al. Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. Clin Oncol 1994; 12: 1164-8.
53. Hejna M, Haverl I, Raderer M. Nonsurgical management of malignant thymoma. Cancer 1999; 85: 1871-84.
54. Bonomi PD, Finkelstein D, Aisner S, Ettinger D. EST2852 phase II trial of cisplatin in metastatic or recurrent thymoma. Am J Clin Oncol 1993;16: 342-5.
55. Highley MS, Underhill CR, Parnis FX, et al. Treatment of invasive thymoma with single-agent ifosfamide. J Clin Oncol 1999; 17: 2737-44.
56. Loehrer PJ, Jiroutek M, Aisner S, et al. Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma. Cancer 2001; 91: 2010-5.
57. Giaccone G, Ardizzon A, Kirkpatrick A, Clerico M, Sahmoud T, van Zandwijk N. Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma: A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 1996; 14: 814-20.
58. Loehrer PJ, Wang W, Johnson DH, Ettinger DS. Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: An Eastern Cooperative Oncology Group Phase II Trial. J Clin Oncol 2004; 22: 293-9.
59. Palmieri G, Montella L, Martignetti A, et al. Somatostatin analogs and prednisone in advanced refractory thymic tumors. Cancer 2002; 94: 1414-20.
60. Gordon MS, Battiato LA, Gonin R, Harrison-Mann BC, Loehrer PJ Sr. A phase II trial of subcutaneously administered recombinant human interleukin-2 in patients with relapsed/refractory thymoma. J Immunother Emphasis Tumor Immunol 1995; 18: 179-84.
61. Hanna N, Gharpure VS, Abnour R, Cornetta K, Loehrer PJ Sr. High-dose carboplatin with etoposide in patients with recurrent thymoma: the Indiana University experience. Bone Marrow Transplant 2001; 28: 435-8.
62. Iwasaki Y, Ohsugi S, Takemura Y, Nagata K, Harada H, Nakagawa M. Multidisciplinary therapy including high-dose chemotherapy followed by peripheral blood stem cell transplantation for invasive thymoma. Chest 2002; 122: 2249-52.
63. Liu JM, Wang LS, Huang BS, et al. Topoisomerase 2α plays a pivotal role in the tumor biology of stage IV thymic neoplasia. Cancer 2006; 109: 502-9.
64. Muss HB, Thor AD, Berry DA, et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994; 330:1260-6.
65. Kruman II, Matylevich NP, Beletsky IP, Afanasyev VN, Umansky SR. Apoptosis of murine BW 5147 thymoma cells induced by dexamethasone and gamma irradiation. J Cell Physiol 1991; 148: 267-73.
66. Lastoria S, Vergara E, Varrella P, et al. In vivo detection of new neoplastic lesions expressing somatostatin receptors using In-111 octreotide. In: Rao RS, Deo MG, Sanghvi LD, Mittra I, eds. Proc XVI International Cancer Congress. Bologna, Italy: Monduzzi, 1994: 685-9.
67. Rauly I, Saint-Laurent N, Delesque N, et al. Induction of a negative autocrine loop by expression of SST2 somatostatin receptor in NIH 3T3 cells. J Clin Invest 1996; 97: 1874-83.
68. Delesque N, Buscail L, Esteve JP, et al. A tyrosine phosphatase is associated with the somatostatin receptor. Ciba Found Symp 1995; 190: 187-96.
69. Buscail L, Esteve JP, Saint LN. Inhibition of cell proliferation by the somatostain analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. Proc Natl Acad U S A 1995; 92: 1580-4.
70. Palmieri G, Lastoria S, Colao A, et al. Successful treatment of a patient with a thymoma and pure red-cell aplasia with octreotide and prednisone. N Eng J Med 1997; 336: 263-5.
71. Tiseo M, Monetti F, Ferrarini M, Serrano J, Chiaramondia M, Ardizzoni A. Dramatic responses to therapy in rare tumors. Case 1. Complete remission to corticosteroids in an octreotide-refractory thymoma. J Clin Oncol 2005; 23: 1578-9.
72. Kirkove C, Berghman J, Noel H, van de Merckf J. Dramatic response of recurrent invasive thymoma to high doses of corticosteroids. Clin Oncol 1992; 4: 64-6.
73. Suster S, Rosai J. Thymic carcinoma. A clinicopathologic study of 60 cases. Cancer 1991; 67: 1025-32.
74. Yoh K, Goto K, Ishii G, et al. Weekly chemotherapy with cisplatin, vincristine, doxorubicin, and etoposide is an effective treatment for advanced thymic carcinoma. Cancer 2003; 98: 926-31.
75. Kitami A, Suzuki T, Kamio Y, Suzuki S. Chemotherapy of thymic carcinoma: Analysis of seven cases and review of the literature. Jpn J Clin Oncol 2001; 31: 601-4.
76. Koizumi T, Takabayashi Y, Yamagishi S, et al. Chemotherapy for advanced thymic carcinoma. Am J Clin Oncol 2002; 25: 266-8.
77. Oshita F, Kasai T, Kurata T, et al. Intensive chemotherapy with cisplatin, doxorubicin, cyclophosphamide, etoposide and granulocyte-stimulating factor for advanced thymoma or thymic cancer: preliminary results. Jap J Clin Oncol 1995; 25: 208-12.
78. Lucchi M, Mussi A, Basolo F, Ambrogi MC, Fontanini G, Angeletti CA. The multimodality treatment of thymic carcinoma. Eur J Cardiothorac Surg 2001; 19: 566-9.
79. Maruyama R, Suemitsu R, Okamoto T, et al. Persistent and aggressive treatment for thymic carcinoma. Oncology 2006; 70: 325-9.
80. Yano T, Hara N, Ichinose Y, Asoh H, Yokoyama H, Ohta M. Treatment and prognosis of primary thymic carcinoma. J Surg Oncol 1993; 52: 255-8.
81. Oguri T, Achiwa H, Kato D, et al. Efficacy of docetaxel as a second-line chemotherapy for thymic carcinoma. Chemotherapy 2004; 50: 279-82.
82. Yamada T, Chiba W, Hitomi S. Thymic basaloid carcinoma. Kyobu Geka 2006; 59: 1154-8.
83. Takeda S, Sawabata N, Inoue M, Koma M, Maeda H, Hirano H. Thymic carcinoma. Clinical institutional experience with 15 patients. Eur J Cardiothorac Surg 204; 26: 401-6.
84. Geffen DB, Benharroch D, Yellin A, Ariad S, Or R, Cohen Y. Multimodal treatment of metastatic thymic carcinoma including high-dose chemotherapy with autologous stem cell transplantation: report of a case with more than 4-year disease-free survival. Am J Clin Oncol 2001; 24: 566-9.
85. Takayama T, Kameya T, Inagaki K, et al. MEB type I associated with mediastinal carcinoid producing parathyroid hormone, calcitonin and chorionic gonadotropin. Pathol Res Pract 1993; 189: 1090-4.
86. Spaggiari L, Pastorino U. Double transmanubrial approach and sternotomy for resection of a giant thymic carcinoid tumor. Ann Thorac Surg 2001; 72: 629-31.
87. Filosso P, Dato G, Ruffini E, Bretti S, Ozzello F, Mancuso M. Multidisciplinary treatment of advanced thymic neuroendocrine carcinoma (carcinoid): report of a successful case and review of the literature. J Thorac Cardiovasc Surg 2004; 127: 1215-9.
88. Pan CC, Jong YJ, Chen YJ. Comparative genomic hybridization analysis of thymic neuroendocrine tumors. Mod Pathol 2005; 18: 358-64.
89. Ekebald S, Sundin A, Janson ET, et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 2007; 13: 2986-91.
90. 6-methylguanine DNA methyltransferase protein expression. Cancer 2006; 106: 175-65.
91. Baas IO, Mulder JW, Offerhaus GJ, Vogelstein B, Hamilton SR. An evaluation of 6 antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 1994; 172: 5-12.
92. Pan CC, Chen PC, Chiang H. KIT (CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomas. J Pathol 2004; 202: 375-81.
93. Henley JD, Cummings OW, Loehrer PJ. Tyrosine kinase receptor expression in thymomas. J Cancer Res Clin Oncol 2004; 130(4): 222-4.
94. Chuah C, Lim TH, Lim AST, Tien SL. Dasatinib induces a response in malignant thymoma. J Clin Oncol 2006; 24: 56e-8.
95. Ioneseu DN, Sasatomi E, Cieply K, Nola M, Dacic S. Protein expression and gene amplification of epidermal growth factor receptor in thymomas. Cancer 2005; 103:630-6.
96. Sasaki H, Ide N, Yukiue H, et al. Arg and DAP3 expression was correlated with human thymoma stage. Clin Exp Metastasis 2004; 21: 507-13.
97. Strobel P, Hartmann M, Jakob, A, et al. Thymic carcinoma with overexpression of mutated KIT and the response to imatinib. N Eng J Med 2004; 350: 2625-6.
98. Allander SV, Nupponen NN, Ringner M, et al. KIT mutations exhibit a remarkably homogenous profile. Cancer Res 2001; 61: 8624-8.
99. Talton CC, Hopkins JD, Walley BD, Kincaid EH. Metastatic thymic carcinoid: A case report. Am Surg 2005; 71: 578-80.
100. Mele G, Pinna S, Melpignano A, et al. What is the best salvage therapy for treatment of isolated CNS relapse in elderly patients with imatinib-responsive Ph(+) ALL? Leuk Res 2007 Apr 24 [Epub ahead of print].
101. McDonald M, McLean T, Belhorn T, et al. Thymic carcinoma in a child with HIV infection. Pediatr Blood Cancer 2005; Nov 29 [Epub ahead of print].
102. Hayashi Y, Obayashi C, Hanioka K, et al. Thymoma: tumor type related to expression of epidermal growth factor (EGF), EGF-receptor, p53, v-erb B and ras p21. Virchows Arch 1995; 426: 43-50.
103. Henley JD, Koukoulis GK, Loehrer PJ. Epidermal growth factor receptor expression in invasive thymoma. J Cancer Res Clin Oncol 2002; 128: 167-70.
104. Rieker RJ, Joos S, Mechtersheimer G, et al. COX-2 upregulation in thymoma and thymic carcinomas. Int J Cancer 2006; 119: 2063-70.
105. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004; 101: 13306-11.
106. Yamaguchi H, Soda H, Kitazaki T, Tsukamoto K, Hayashi T, Kohno S. Thymic carcinoma with epidermal growth factor receptor gene mutations. Lung Cancer 2006: 52: 261-2.
107. Suzuki M, Chen H, Shigematsu. H, et al. Aberrant methylation: common in thymic carcinomas, rare in thymomas. Oncol Rep 2005; 14: 1621-4.
108. Pan CC, Chen PC, Wang LS, Lee JY, Chiang H. Expression of apoptosis-related markers and HER-2/neu in thymic epithelial tumours. Histopathology 2003; 43: 165-72.
109. Sasaki H, Yukiue H, Kobayashi Y, et al. Elevated serum vascular endothelial growth factor and basic fibroblast growth factor levels in patients with thymic epithelial neoplasms. Surg Today 2001; 31: 1038-40.
110. Fukiwake N, Kase S, Yamazaki K, Yano T, Sugimachi K. Correlation between clinical aggressiveness of thymic epithelial tumors and expression of tumor suppressor gene products (p53, p27). Fukuoka Igaku Zasshi 1999; 90: 339-41.
111. Gal AA, Sheppard MN, Nolen J, Cohen C. p53, cellular proliferation, and apoptosis-related factors in thymic neuroendocrine tumors. Modern Pathology 2004; 17: 33-9.
112. Hiroshima K, Iyoda A, Toyozaki T, et al. Proliferative activity and apoptosis in thymic epithelial neoplasms. Mod Path 2002; 15: 1326-32.
113. Hirabayashi H, Fujii Y, Sakaguchi M, et al. p16INK4, pRB, p53 and cyclin D1 expression and hyprmethylation of CDKN2 gene in thymoma and thymic carcinoma. Int J Cancer 1997; 73: 639-44.
114. Tiffet O, Nicholson AG, Ladas G, Sheppard MN, Goldstraw PG. A clinicopathologic study of 12 neuroendocrine tumors arising in the thymus. Chest 2003; 124: 141-6.
115. De Montpreville VT, Macchiarini P, Dulmet E. Thymic neuroendocrine carcinoma (carcinoid): a clinicpathological study of fourteen cases. J Thorac Cardiovasc Surg 1996; 111: 134-41.
116. Hino N, Kondo K, Miyoshi T, Uyama T, Monden Y. High frequency of p53 protein expression in thymic carcinoma but not thymoma. Br J Cancer 1997; 76: 1361-6.
117. Tomita M, Matsuzaki Y, Onitsuka T. Relationship between expression of cancer-related proteins and tumor invasiveness in thymoma. Eur J Cardiothorac Surg 2002; 21: 596.
118. Ambrosini G, Adida C, Altier DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997; 3: 917-21.
119. Hishima T, Fukuyama M, Hayashi Y, et al. CD70 expression in thymic carcinoma. Am J Surg Pathol 2000; 24: 742-6.
120. McEarchern JA, Oflazoglu E, Francisco L, et al. Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities. Blood 2006; 109: 1185-92.
121. Israel BF, Gulley M, Elmore S, Ferrini S, Feng WH, Kenney SC. Anti-CD70 antibodies: a potential treatment for EBV+CD70- expressing lymphomas. Molec Cancer Ther 2005; 4: 2037-44.
122. Tasaki A, Akiyoshi T, Koga K, et al. Immunohistochemical staining of hedgehog pathway-related proteins in human thymomas. Anticancer Res 2005; 25: 3697-01.
123. French CA, Miyoshi I, Kubonishi I, Grier HE, Perez-Atayde AR, Fletcher JA. BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma. Cancer Res 2003; 63: 304-7.
124. French CA, Miyoshi I, Aster JC, et al. BRD4 bromodomain gene rearrangement in aggressive carcinoma with translocation t(15; 19). Am J Pathol 2001; 159: 1987-92.
125. Raymond E, ten Bokkel Huinink WW, Taieb J, et al. Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor, administered as a one-hour infusion every three weeks in patients with advanced cancer. J Clin Oncol 2002; 20: 3508-21.
126. Rowinsky EK, Johnson TR, Geyer CE, et al. DX8951f, a hexacyclic camptothecin analog, on a daily-time-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies. J Clin Oncol 2000; 18: 3151-63.
127. Garrison MA, Hammond LA, Geyer CE, et al. A Phase I and pharmacokinetic study of exatecan mesylate administered as a protracted 21-day infusion in patients with advanced solid malignancies. Clin Cancer Res 2003; 9: 2527-37.
128. Awada A, Hendlisz A, Gil T, et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced refractory solid tumors. Br J Cancer 2005; 92: 1855-61.
129. Dy GK, Thomas JP, Wilding G, et al. A phase I and pharmacological trial of two schedules of the proteosome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer. Clin Cancer Res 2005; 11: 3410-6.
130. Editorial. Safeguarding clinical trials. Nature Med 2007; 13: 107.
131. Hearn J, Sullivan R. The impact of the 'Clinical Trials' directive on the cost and conduct of non-commercial trials in the UK. Eur J Cancer 2007; 43: 8-13.
132. Thomas CR, Wright CD, Loehrer PJ. Thymoma: state of the art. J Clin Oncol 1999; 17: 2280-9.